The current model of antibiotic discovery is not
delivering new drugs fast enough to combat current levels of antibiotic
resistance. Scientific difficulties, an unfavorable regulatory environment,
multiple mergers, and low economic returns associated with antibiotic
development have driven many pharmaceutical companies out of the field.
Although the drug research regulatory environment has improved since then,
major scientific hurdles still hinder the discovery and development of new antimicrobial agents. With the
increasing resistance of bacteria and the decline in the development of new
antibiotics and drug research, the appropriate
use of older antibiotics has become even more imperative. Clindamycin is a
lincosamide antibiotic approved for adults and children as the drug of choice
for systemic treatment in clinical trials of infections caused by anaerobic
staphylococci, streptococci, and gram-positive bacteria. Because of its
properties and high bioavailability, it is often used as part of an oral
multimodal alternative to prolonged parenteral antibiotic regimens, for the
treatment of infections associated with bones and joints or prosthetics. In
addition, drug interactions derived from CYP3A4 inducers and inhibitors, and
data on the impact of disease states on the CYP system, are still limited.
These kinds of impacts make an important to drug discovery and drug
development.